CRISPR therapy suppresses accelerated progeria in mice

The Salk team has highlighted a way to suppress a rare condition in mice, causing accelerated progeria, by using CRISPR/Cas9 gene-editing technology.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Novel treatment for progeria sheds light on genetic component of aging.

There is still much to disentangle when it comes to understanding the genetic basis of aging. The body’s circuitry is complex and the processes by which it ages are woven over each other often more than one time and in stupefying combinations. That’s not to discourage us from working with what we know, however, which is exactly what scientists at the Salk Institute have been able to do. And they have done so with results that indicate they may have found a way to slow down the process.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Ben Turner

Staff Writer

Ben Turner is a writer and journalist based in London. He graduated in 2015 with a Master’s degree in Physics. He is particularly interested in the translation of early scientific discoveries into cutting-edge tech.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oura spends $625m to put doctors behind its smart ring

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE